乌干达镰状细胞贫血儿童羟基脲治疗中的神经认知获益:18个月中期试验结果
该30个月单臂开放标签试验纳入264例3至9岁乌干达镰状细胞贫血患儿,羟基脲滴定至最大耐受剂量,18个月时三个神经认知域z评分较基线均显著改善,但未调整评分仍与年龄负相关,作者认为早期治疗对最佳效果是必要的。
要点
- 18个月时认知域z评分从-0.54±1.10改善至-0.07±1.16(P<.001)。
- 注意力域z评分从-0.07±1.01改善至0.27±0.84(P<.001)。
- 执行功能域z评分从-0.06±0.62改善至0.08±0.72(P=.010)。
核心结论
- 羟基脲治疗改善了撒哈拉以南非洲镰状细胞贫血儿童的神经认知功能,可能部分得益于练习效应,作者认为需要早期治疗以获得最佳效果。
研究设计与样本
- 30个月单臂开放标签试验,纳入264例3至9岁乌干达镰状细胞贫血患儿,羟基脲滴定至最大耐受剂量。
- 110例无镰状细胞贫血的同胞对照接受平行神经认知测试以建立年龄标准化z评分。
主要发现
- 18个月时平均每日羟基脲剂量为25.4 mg/kg。
- 认知域z评分从基线-0.54±1.10改善至-0.07±1.16(P<.001)。
- 注意力域z评分从基线-0.07±1.01改善至0.27±0.84(P<.001)。
- 执行功能域z评分从基线-0.06±0.62改善至0.08±0.72(P=.010)。
- 18个月时各指标与对照无差异;认知障碍比例从入组时8.7%降至4.0%,对照为1.6%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Children with sickle cell anemia (SCA) frequently develop progressive neurocognitive impairment. We aimed to determine effects of hydroxyurea therapy on neurocognitive function in Ugandan children with SCA by comparing levels at enrollment to a planned 18-month interim assessment. Ugandan children (N = 264) aged 3 to 9 years attending SCA clinic were enrolled and treated in a 30-month, single-arm, open-label trial with escalation to maximum tolerated dose. Sibling controls (N = 110) without SCA underwent parallel neurocognitive testing to establish age-normalized z scores for comparison. At enrollment, mean participant age was 5.6 ± 1.2 years, with comparable socioeconomic status and caregiver education vs. controls. Month 18 mean daily hydroxyurea dose was 25.4 mg/kg. We found significantly improved participant z scores vs. baseline in all 3 neurocognitive domains tested: cognition: -0.54 ± 1.10 vs. -0.07 ± 1.16, P < .001; attention: -0.07 ± 1.01 vs. 0.27 ± 0.84, P < .001; and executive function: -0.06 ± 0.62 vs. 0.08 ± 0.72, P = .010. No month-18 measures differed from controls. Participants with SCA and cognitive impairment declined from 8.7% at enrollment to 4.0%, vs. 1.6% of controls; with decreased mean TCD velocity. Improved neurocognitive treatment z-scores were associated with higher baseline scores and socioeconomic status, hydroxyurea-associated lower TCD velocity, and hematological-induced effects, eg higher hemoglobin. Despite improvement, unadjusted neurocognitive scores remained negatively associated with age. Hydroxyurea therapy improved SCA neurocognitive function in sub-Saharan children, potentially aided by practice effects. Early treatment is needed for optimal impact. Our ongoing trial will assess impact from longer-term hydroxyurea therapy. This trial was registered at www.ClinicalTrials.gov as #NCT04750707.
引用
- Naggayi SK, Kalibbala D, Mboizi V, et al. Neurocognitive gains among Ugandan children with sickle cell anemia on hydroxyurea: 18-month interim trial results. Blood Adv. 2025. PMID: 40085947. doi:10.1182/bloodadvances.2024015073
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。